Emibetuzumab
Emibetuzumab
Emibetuzumab (pronunciation: em-ee-bet-oo-zoo-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is currently under investigation in clinical trials.
Etymology
The name "Emibetuzumab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The prefix "Emi-" is randomly assigned, the infix "-betu-" indicates that the drug targets tumors, and the suffix "-mab" denotes that it is a monoclonal antibody.
Mechanism of Action
Emibetuzumab works by binding to a specific protein found on the surface of cancer cells, known as MET. By binding to MET, Emibetuzumab can block the signals that tell the cancer cells to grow and divide, thereby slowing or stopping the growth of the cancer.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- MET (gene): A gene that makes a protein called MET, which is involved in sending signals within cells and can become overactive in some types of cancer.
- Tumor: An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Clinical Trials
Emibetuzumab is currently being studied in clinical trials for its effectiveness in treating various types of cancer, including non-small cell lung cancer and gastric cancer.
External links
- Medical encyclopedia article on Emibetuzumab
- Wikipedia's article - Emibetuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski